%PDF-1.6 % 1 0 obj <>/Font<>/ProcSet[/PDF/Text]/ExtGState 164 0 R/XObject 165 0 R>>/Rotate 0/StructParents 8/Type/Page/Tabs/S>> endobj 2 0 obj <>stream /CS0 cs 1 scn 36 766.552 576 -694.552 re f /P <>BDC q 36 72 576 695 re W n BT 0 scn /TT0 1 Tf 0.016 Tw 10.5517 0 0 10.5517 60.8276 757.2414 Tm [(forms,)-45( strengths,)-21( and)-38( routes)-44( of)-48( administration)-11( as)-3( the)-22( drugs)-28( to)-48( be)-6( marketed)-8( as)-3( SIMLANDI.)-58( None)-22( of)]TJ ET EMC Q BT /P <>BDC 0 scn /TT0 1 Tf 0.016 Tw 10.5517 0 0 10.5517 60.8276 744.2069 Tm [(these)-25( formulations)-25( of)-48( HUMIRA)-56( was)-45( marketed)-8( in)-45( Canada)-27( by)-3( AbbVie)-11( at)-48( the)-22( time)-52( JAMP)-39( submitted)-18( its)]TJ EMC /P <>BDC 0 -1.235 TD [(NDS.)-23( Hereinafter,)-11( these)-25( drugs)-28( \(DINs)-33( 02458349,)-39( 02458357,)-39( and)-38( 02466872\))-42( are)-26( referred)-28( to)-48( as)-3( the)]TJ EMC /P <>BDC 0 -1.235 TD [(\223referenced)-5( HUMIRA)-56( products\224.)]TJ EMC /P <>BDC 0 -2.176 TD [(In)-48( its correspondence)-6( with)-46( Health)-51( Canada\222s)-11( Office)-35( of)-48( Submissions)-38( and)-38( Intellectual)-43( Property)-45( \(\223OSIP\224\),)]TJ EMC /P <>BDC 0 -1.235 TD [(and)-38( after)-58( being)-25( told)-35( that)-38( their)-55( NDS)-7( was)-46( incomplete,)-5( JAMP)-39( submitted)-18( Form)-20( Vs)-9( on)-6( a)-32( \223without)]TJ EMC /P <>BDC T* [(prejudice\224)-22( basis,)-35( yet)-19( took)-51( the)-22( position)-25( that)-38( it)-29( was)-45( not)-22( required)-38( to)-48( comply)-9( with)-46( s)-29( 5\(1\))-45( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf 0 Tw (PM\(NOC\))Tj EMC /P <>BDC T* [(Regulations,)-30( )]TJ EMC /P <>BDC /TT0 1 Tf 0.016 Tw 5.882 0 Td [(as)-3( they)-51( were)-9( not)-22( a)-32( \223second)-31( person\224)-22( as)-3( defined)-14( therein)-2( because)-44( the)-22( referenced)]TJ EMC /P <>BDC -5.882 -1.235 Td [(HUMIRA)-56( products)-47( had)-38( not)-22( been)-11( marketed)-8( in)-45( Canada)-27( for)-9( several)-12( years)-26( and)-38( therefore)-57( they)-51( were)-9( not)]TJ EMC /P <>BDC T* [(drugs)-28( \223marketed)-28( in)-46( Canada\224)-47( as)-3( required)-38( by)-3( s)-29( 5\(1\).)]TJ EMC /P <>BDC /TT1 1 Tf 0 -2.176 TD [(5)-32( \(1\))-13( If)-32( a)-32( second)-11( person)-2( files)-45( a)-32( submission)-58( for)-9( a)-32( notice)-38( of)-48( compliance)-2( in)-45( respect)-15( of)-48( a)-32( drug)-58( and)-38( the)]TJ EMC /P <>BDC 0 -1.235 TD [(submission)-58( directly)-9( or)-52( indirectly)-55( compares)-22( the)-22( drug)-58( with,)-3( or)-52( makes)-55( reference)-11( to,)-6( )]TJ EMC /P <>BDC /TT2 1 Tf [(another)-39( drug)]TJ EMC ET /P <>BDC BT /TT2 1 Tf 10.5517 0 0 10.5517 60.8276 580.9656 Tm [(marketed)-25( in)-52( Canada)]TJ ET /CS0 CS 0 SCN 0.621 w q 1 0 0 1 60.8276 580.3448 cm 0 0 m 101.793 0 l S Q EMC BT /P <>BDC /TT2 1 Tf 0 Tw 10.5517 0 0 10.5517 162.6207 580.9656 Tm ( )Tj EMC /P <>BDC /TT1 1 Tf 0.016 Tw 0.294 0 Td [(under)-31( a)-32( notice)-38( of)-48( compliance)-2( issued)-51( to)-48( a)-32( first)-36( person)-2( and)-38( in)-45( respect)-15( of)-48( which)-32( a)]TJ EMC /P <>BDC -9.941 -1.235 Td [(patent)-43( list)-13( has)-35( been)-11( submitted,)-34( the)-22( second)-11( person)-2( shall)-3( include)-8( in)-45( the)-22( submission)-58( the)-22( required)]TJ EMC /P <>BDC T* [(statements)-50( or)-52( allegations)-43( set)-19( out)-22( in)-46( subsection)-43( \(2.1\).)-19( )]TJ EMC /P <>BDC /TT0 1 Tf [([Emphasis)-38( ours])]TJ EMC /P <>BDC 0 -2.176 TD [(Health)-51( Canada\222s)-11( Office)-35( of)-48( Patented)-56( Medicines)-28( and)-38( Liaison)-8( \(\223OPML\224\))-10( later)-55( advised)-24( AbbVie)-11( of)-48( its)]TJ EMC /P <>BDC 0 -1.235 TD [(preliminary)-52( view)-59( that)-38( the)-22( referenced)-43( HUMIRA)-56( products)-47( were)-9( indeed)-57( not)-22( currently)-48( being)-24( marketed)-8( in)]TJ EMC /P <>BDC 0 -1.235 TD [(Canada.)-43( Therefore,)-34( the)-22( referenced)-43( HUMIRA)-56( products)-47( did)-19( not)-22( trigger)-48( s)-29( 5\(1\))-45( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf 0 Tw (PM\(NOC\))Tj EMC /P <>BDC 0 -1.235 TD (Regulations)Tj EMC /P <>BDC /TT0 1 Tf 5.294 0 Td (.)Tj EMC /P <>BDC 0.016 Tw -5.294 -2.176 Td [(However,)-12( AbbVie)-11( argued)-5( that)-38( JAMP)-39( nevertheless)-37( made)-28( reference)-11( to)-48( a)-32( drug)-58( product)-18( they)-51( marketed)]TJ EMC /P <>BDC T* [(in)-45( Canada,)-44( thus)-51( falling)-35( within)-32( s)-29( 5\(1\))-45( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 29.118 0 Td [(.)-16( Namely,)-39( AbbVie)-11( argued)-5( that)]TJ EMC /P <>BDC -29.118 -1.235 Td [(JAMP)-39( SIMLANDI)-42( indirectly)-55( made)-28( reference)-11( to)-48( their)-55( HUMIRA)-56( 20)-6( mg/0.2)-2( mL)-23( pre)-26(-)-20(filled)-3( syringe)]TJ EMC /P <>BDC T* [(because)-43( both)-54( products)-47( had)-38( the)-22( same)-26( drug)-58( concentration)-56( \(i.e.,)-55( 100)-38( mg/mL\).)]TJ EMC /P <>BDC 0 -2.176 TD [(Hence,)-8( the)-22( issue)-19( was)-45( to)-48( determine)-25( whether)-31( a)-32( second)-11( person)-2( seeking)-25( approval)-47( for)-9( a)-32( drug)-58( with)-45( a)]TJ EMC /P <>BDC 0 -1.235 TD [(specific)-19( dosage)-14( strength)-34( could)-22( be)-6( considered)-50( to)-48( indirectly)-55( refer)-3( to)-48( a)-32( \223drug)-19( marketed)-8( in)-45( Canada\224)-47( with)]TJ EMC /P <>BDC 0 -1.235 TD [(another)-21( dosage)-14( strength)-34( but)-22( having)-54( the)-22( same)-26( concentration.)]TJ EMC /H2 <>BDC /TT3 1 Tf 0 -2.176 TD [(The)-45( Minister\222s)-38( Decision)]TJ EMC /P <>BDC /TT0 1 Tf T* [(After)-6( reviewing)-12( submissions)-28( from both)-54( parties,)-15( the)-22( OPML)-48( issued)-51( its final)-48( decision)-38( on)-6( December)-35( 23,)]TJ EMC /P <>BDC 0 -1.235 TD [(2021,)-27( in)-45( which)-32( it)-29( confirmed)-22( its preliminary)-52( determination)-60( that)-38( JAMP)-39( was)-45( not)-22( a)-32( second)-11( person)-2( for)-9( the)]TJ EMC /P <>BDC 0 -1.235 TD [(purposes)-5( of)-48( s)-29( 5\(1\))-46( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 21.412 0 Td [(,)-16( and)-38( the)-22( corresponding)-17( obligations)-44( did)-19( not)-22( arise)]TJ EMC /P <>BDC -21.412 -1.235 Td [(unless)-51( the)-22( second)-11( person\222s)-44( NDS)-7( \223directly)-29( or)-52( indirectly)-55( compares)-22( the)-22( drug)-58( with,)-3( or)-52( reference\224)-31( to)]TJ EMC /P <>BDC 0 -1.235 TD [(\223another)-41( drug)-58( marketed)-8( in)-46( Canada\224.)]TJ EMC /P <>BDC 0 -2.176 TD [(The)-42( OPML)-48( found)-27( that)-38( \223another)-41( drug)-58( marketed)-8( in)-46( Canada\224)-47( must)-9( be)-6( interpreted)-43( to)-48( be)-6( specific)-19( with)]TJ EMC /P <>BDC 0 -1.235 TD [(respect)-15( to)-48( strength,)-50( dosage)-14( form,)-16( and)-38( route)-15( of)-48( administration)-11( \(i.e.,)-55( it)-29( is)-43( DIN)-43(-)-20(specific\).\224)-16( The)-42( Minister)]TJ EMC /P <>BDC 0 -1.235 TD [(found)-27( that)-38( the)-22( \223indirect\224)-52( comparison)-8( of)-48( s)-29( 5\(1\))-46( did)-19( not)-22( expand)-14( the)-22( scope)-38( of)-48( the)-22( drugs)-28( for)-9( which)-32( a)]TJ EMC /P <>BDC T* [(second)-11( person)-2( must)-9( address)-31( the)-22( patents)-14( listed)-19( on)-6( the)-22( Patent)-50( Register)-42( beyond)-14( the)-22( DIN)-43(-)-20(specific)]TJ EMC /P <>BDC 0 -1.235 TD [(\223another)-41( drug\224.)-35( Hence,)-8( the)-22( HUMIRA)-56( 20)-6( mg/0.2)-2( mL)-23( pre)-26(-)-20(filled)-3( syringe)-12( marketed)-8( by)-3( AbbVie)-11( was)-45( not)-22( a)]TJ EMC /P <>BDC 0 -1.235 TD [(proper)-51( reference)-11( product)-18( for)-9( JAMP\222s)-23( 40)-6( mg/0.4)-2( mL)-23( pre)-26(-)-20(filled)-3( syringe,)-28( 40)-6( mg/0.4)-2( mL)-23( auto)-54(-)-20(injector)]TJ EMC /P <>BDC T* [(pen,)-54( and)-38( 80)-6( mg/0.8)-2( mL)-23( pre)-26(-)-20(filled)-3( syringe.)]TJ EMC /P <>BDC 0 -2.176 TD [(Accordingly,)-25( on)-6( January)-31( 5,)-48( 2022,)-27( the)-22( Minister)-29( issued)-51( NOCs)-43( to)-48( JAMP)-39( and)-38( JAMP)-39( launched)-60( its)]TJ EMC /P <>BDC 0 -1.235 TD [(products)-47( on)-6( April)-59( 13,)-22( 2022.)]TJ EMC /P <>BDC 0 -2.176 TD [(Subsequently,)-16( AbbVie)-11( sought)-57( judicial)-3( review)-52( of)-48( these)-25( two)-32( related)-2( decisions)-8( of)-48( the)-22( Minister,)-45( the)-22( result)]TJ EMC /P <>BDC 0 -1.235 TD [(of)-48( which)-32( is)-43( the)-22( presently)-2(-)-20(discussed)-24( Federal)-22( Court)-26( decision.)]TJ EMC /P <>BDC 0 -2.176 TD [(Ultimately,)-39( the)-22( Federal)-22( Court)-25( agreed)-5( with)-45( the)-22( Minister.)-45( Specifically,)-15( the)-22( Federal)-22( Court)-26( concluded)-30( that)]TJ EMC ET /P <>BDC q 36 72 576 695 re W n BT /TT1 1 Tf 10.5517 0 0 10.5517 60.8276 74.4828 Tm [(inter)-55( alia)]TJ ET EMC /P <>BDC BT /TT0 1 Tf 10.5517 0 0 10.5517 101.7931 74.4828 Tm [( the)-22( following)-51( findings)-25( by)-3( the)-22( Minister)-29( were)-9( reasonable:)]TJ ET EMC Q endstream endobj 3 0 obj <> endobj 4 0 obj <>/Font<>/ProcSet[/PDF/Text]/ExtGState 188 0 R/XObject 189 0 R>>/Rotate 0/StructParents 15/Type/Page/Tabs/S>> endobj 5 0 obj [8 0 R] endobj 6 0 obj <>stream /CS0 cs 1 scn 36 766.552 576 -431.379 re f BT /LBody <>BDC 0 scn /TT0 1 Tf 0.008 Tw 8.6897 0 0 8.6897 85.6552 747.3104 Tm [(that)-46( the)-39( term \223another)-62( drug\224)-23( in)-8( s 5\(1\))-8( of)-23( the)-38( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-41( Regulations)]TJ EMC /LBody <>BDC /TT0 1 Tf 29.5 0 Td [( is)-64( confined)-6( to)-23( the)-38( drug)-70( products)-22( identified)-69( by)]TJ EMC /LBody <>BDC -29.5 -1.214 Td [(Health)-39( Canada,)-6( and)-46( that)-46( these)-54( products)-22( must)-47( have)-46( an)-31( identical)-46( dosage)-6( form,)-8( strength,)-38( and)-46( route)-7( of)-23( administration)]TJ EMC /LBody <>BDC 0 -1.214 TD [(to)-23( the)-38( drug)-70( product)-22( of)-23( the)-39( second)-62( person.)]TJ EMC /LBody <>BDC T* [(that)-46( s 5\(1\))-8( of)-23( the)-39( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-41( Regulations)]TJ EMC /LBody <>BDC /TT0 1 Tf 17.714 0 Td [( applies)-46( only)-23( where)-63( a)-15( second)-62( person)-14( files)-8( a)-15( submission)-70( for)-47( an)-31( NOC)-64( that)-46( \(1\))]TJ EMC /LBody <>BDC -17.714 -1.214 Td [(directly)-47( or)-40( indirectly)-55( compares)-39( its drug,)-7( or)-39( makes)-55( reference)-62( to)-23( \223another)-62( drug\224,)-31( \(2\))-64( that)-46( other)-7( drug)-70( is)-64( marketed)-46( in)]TJ EMC /LBody <>BDC T* [(Canada)-69( under)-14( an)-31( NOC)-64( issued)-39( to)-23( a)-15( first)-32( person,)-22( and)-46( \(3\))-64( that)-46( other)-7( drug)-70( is)-64( a)-15( drug)-70( in)-8( respect)-7( of)-23( which)-15( the)-39( first)-32( person)]TJ EMC /LBody <>BDC 0 -1.214 TD [(has)-31( submitted)-22( a)-15( patent)-6( list;)]TJ EMC /LBody <>BDC 0 -1.214 TD [(that)-46( a)-15( drug)-70( that)-46( is)-64( not)-39( marketed)-46( is)-64( not)-39( eligible)-31( for)-47( the)-39( protections)-38( under)-14( the)-38( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-40( Regulations)]TJ EMC /LBody <>BDC /TT0 1 Tf 43.714 0 Td [(;)-8( and)]TJ EMC /LBody <>BDC -43.714 -1.214 Td [(that)-46( JAMP)-47( was)-8( not)-39( a)-15( second)-62( person)-14( under)-14( s 5\(1\))-8( for)-47( the)-39( simple)-39( reason)-14( that)-46( AbbVie)-62( was)-8( not)-38( marketing)-38( in)-8( Canada)]TJ EMC /LBody <>BDC T* [(the)-39( HUMIRA)-56( drugs)-70( that)-46( JAMP)-47( relied)-55( on)-31( for)-47( its NDS.)]TJ EMC /H2 <>BDC /TT2 1 Tf 0 Tw 10.5517 0 0 10.5517 60.8276 631.8621 Tm (Conclusion)Tj EMC /P <>BDC /TT0 1 Tf 0.016 Tw 0 -2.176 TD [(The)-42( Minister's)-44( decisions,)-25( as)-3( well)-43( as)-3( the)-22( Federal)-22( Court's)-40( finding)-54( that)-38( they)-51( were)-9( reasonable)-53( \(pending)]TJ EMC /P <>BDC 0 -1.235 TD [(any)-35( appeal\),)-34( emphasizes)-18( one)-38( of)-48( the)-22( statutory)-47( objectives)-25( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 38.235 0 Td [(,)-16( namely)-12( to)]TJ EMC /P <>BDC -38.235 -1.235 Td [(provide)-15( a)-32( patent)-43( enforcement)-30( mechanism)-6( only)-48( in)-45( relation)-15( to)-48( products)-47( that)-38( are)-26( in)-45( fact)-35( available)-54( to)]TJ EMC /P <>BDC T* [(Canadians.)-60( This)-52( also)-48( clarifies)-23( certain)-58( practical)-42( effects)-54( of)-48( this)-32( statutory)-47( objective,)-11( namely)-12( that)-38( the)]TJ EMC /P <>BDC 0 -1.235 TD [(enforcement)-30( mechanism)-6( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 24.176 0 Td [( is)-43( only)-48( available)-54( to)-48( an)-6( innovator)-5( that)-38( markets)]TJ EMC /P <>BDC -24.176 -1.235 Td [(its innovative)-27( drug)-58( in)-45( Canada,)-43( and)-38( that)-38( s)-29( 5\(1\))-45( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 33.529 0 Td [( applies)-8( only)-48( to)-48( reference)]TJ EMC /P <>BDC -33.529 -1.235 Td [(drug)-58( products)-47( that)-38( are)-26( identical)-38( down)-22( to)-48( a)-32( DIN)-43(-)-20(specific)-19( level)-3( with)-45( the)-22( drug)-58( to)-48( be)-6( approved.)]TJ EMC /P <>BDC 0 -2.176 TD [(However,)-12( this)-32( does)-8( not)-22( mean)-28( that)-38( innovators)-34( are)-26( entirely)-12( without)-8( recourse)-51( when)-22( it)-29( comes)-55( to)-48( drugs)]TJ EMC /P <>BDC 0 -1.235 TD [(they)-51( are)-26( not)-22( marketing)-22( in)-46( Canada.)-43( Under)-42( such)-6( circumstances,)-38( while)-16( innovators)-34( may)-52( not)-22( be)-6( able)-51( to)]TJ EMC /P <>BDC 0 -1.235 TD [(utilize)-32( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PMNOC)-43( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 13.941 0 Td [( to)-48( prevent)-18( a)-32( NOC)-13( from being)-25( issued)-51( to)-48( a)-32( competitor,)-54( it)-29( can)]TJ EMC /P <>BDC -13.941 -1.235 Td [(nonetheless)-20( commence)-51( normal)-3( patent)-43( infringement)-27( proceedings)-23( in)-45( Federal)-22( Court.)]TJ EMC /P <>BDC 0 Tw 0 -2.176 TD ( )Tj EMC /P <>BDC 0.016 Tw 0 -2.176 TD [(A)-39( copy)-6( of)-48( this)-32( decision,)-54( )]TJ EMC /P <>BDC /TT1 1 Tf [(AbbVie)-11( Corporation)-11( v.)-45( Canada)-27( \(Health\))]TJ EMC /P <>BDC /TT0 1 Tf 28.353 0 Td [(,)-16( 2022)-11( FC)-20( 1209,)-27( is)-43( available)-54( )]TJ EMC ET /Link <>BDC BT /CS1 cs 0 0 1 scn /TT0 1 Tf 0 Tw 10.5517 0 0 10.5517 496.5517 422.6897 Tm (here)Tj ET /CS1 CS 0 0 1 SCN 0.621 w q 1 0 0 1 496.5517 422.069 cm 0 0 m 21.724 0 l S Q EMC BT /P <>BDC /CS0 cs 0 scn /TT0 1 Tf 10.5517 0 0 10.5517 518.2758 422.6897 Tm (.)Tj EMC /P <>BDC -43.353 -2.176 Td ( )Tj EMC /P <>BDC 0.016 Tw T* [(Our)-39( intellectual)-41( property)-38( team)-12( would)-35( be)-6( happy)-41( to)-48( help)-51( you)-35( with)-45( any)-35( questions)-14( you)-35( may)-52( have)]TJ EMC /P <>BDC 0 -1.235 TD [(regarding)-11( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 0 Tw 16.235 0 Td (.)Tj EMC ET endstream endobj 7 0 obj <> endobj 8 0 obj <>/BS<>/Border[0 0 0]/Rect[497.0 420.0 519.0 431.0]/StructParent 16/Subtype/Link/Type/Annot>> endobj 9 0 obj <> endobj 10 0 obj <> endobj 11 0 obj <>>> endobj 12 0 obj <> endobj 13 0 obj <> endobj 14 0 obj <> endobj 15 0 obj [35 0 R null 36 0 R 34 0 R null 37 0 R 25 0 R null null 27 0 R 27 0 R 27 0 R 27 0 R null null null 29 0 R null null 31 0 R null null null null 38 0 R 38 0 R null 39 0 R null 39 0 R 39 0 R null 40 0 R null 41 0 R null 42 0 R 42 0 R 42 0 R null 43 0 R 43 0 R null 44 0 R 44 0 R 44 0 R 44 0 R null 45 0 R 45 0 R 45 0 R 45 0 R] endobj 16 0 obj [45 0 R 45 0 R 45 0 R 45 0 R null 46 0 R 46 0 R 46 0 R null 46 0 R null 46 0 R 46 0 R 46 0 R 46 0 R null null 47 0 R null 47 0 R null 47 0 R null null null 47 0 R 47 0 R 47 0 R null 47 0 R null 47 0 R 47 0 R null 48 0 R 48 0 R 48 0 R null 48 0 R null 48 0 R 48 0 R null 49 0 R 49 0 R null 49 0 R 49 0 R 49 0 R 49 0 R null 50 0 R 50 0 R 50 0 R null 51 0 R null 52 0 R 52 0 R 52 0 R null 52 0 R 52 0 R 52 0 R 52 0 R null 53 0 R 53 0 R 53 0 R 53 0 R 53 0 R 53 0 R 53 0 R null 54 0 R 54 0 R null 55 0 R 55 0 R null 56 0 R null 56 0 R 56 0 R] endobj 17 0 obj [77 0 R null 80 0 R 79 0 R 79 0 R 79 0 R null null 73 0 R null 76 0 R 75 0 R 75 0 R 75 0 R 75 0 R null null 69 0 R null 72 0 R 71 0 R null null 68 0 R 68 0 R null 58 0 R null 59 0 R 59 0 R null 59 0 R 59 0 R 59 0 R 59 0 R 59 0 R null 59 0 R 59 0 R 59 0 R null 59 0 R 59 0 R 59 0 R null 60 0 R 60 0 R 60 0 R null 60 0 R 60 0 R 60 0 R null 61 0 R null 19 0 R null 19 0 R 19 0 R null 18 0 R 19 0 R null 62 0 R null 63 0 R 63 0 R null 63 0 R 63 0 R] endobj 18 0 obj <>]/P 19 0 R/Pg 4 0 R/S/Link>> endobj 19 0 obj <> endobj 20 0 obj <> endobj 21 0 obj <> endobj 22 0 obj <> endobj 23 0 obj <> endobj 24 0 obj <> endobj 25 0 obj <> endobj 26 0 obj <> endobj 27 0 obj <> endobj 28 0 obj <> endobj 29 0 obj <> endobj 30 0 obj <> endobj 31 0 obj <> endobj 32 0 obj <> endobj 33 0 obj <> endobj 34 0 obj <> endobj 35 0 obj <> endobj 36 0 obj <> endobj 37 0 obj <> endobj 38 0 obj <> endobj 39 0 obj <> endobj 40 0 obj <> endobj 41 0 obj <> endobj 42 0 obj <> endobj 43 0 obj <> endobj 44 0 obj <> endobj 45 0 obj <><><><>]/P 20 0 R/Pg 95 0 R/S/P>> endobj 46 0 obj <> endobj 47 0 obj <> endobj 48 0 obj <> endobj 49 0 obj <> endobj 50 0 obj <> endobj 51 0 obj <> endobj 52 0 obj <> endobj 53 0 obj <> endobj 54 0 obj <> endobj 55 0 obj <> endobj 56 0 obj <> endobj 57 0 obj <> endobj 58 0 obj <> endobj 59 0 obj <> endobj 60 0 obj <> endobj 61 0 obj <> endobj 62 0 obj <> endobj 63 0 obj <> endobj 64 0 obj <> endobj 65 0 obj <> endobj 66 0 obj <> endobj 67 0 obj <> endobj 68 0 obj <> endobj 69 0 obj <> endobj 70 0 obj <> endobj 71 0 obj <> endobj 72 0 obj <> endobj 73 0 obj <> endobj 74 0 obj <> endobj 75 0 obj <> endobj 76 0 obj <> endobj 77 0 obj <> endobj 78 0 obj <> endobj 79 0 obj <> endobj 80 0 obj <> endobj 81 0 obj <> endobj 82 0 obj [4 0 R/XYZ 0 1765.0 null] endobj 83 0 obj <> endobj 84 0 obj <> endobj 85 0 obj <> endobj 86 0 obj (file:///C:/ColdFusion2018/cfusion/tmpCache/CFPDFServiceFileServlet/_cf_pdf/PDFFILE_593784108.html) endobj 87 0 obj <> endobj 88 0 obj <> endobj 89 0 obj <>stream 2024-03-29T08:29:11-04:00 2024-03-29T08:29:11-04:00 2024-03-29T08:29:11-04:00 uuid:716ac5a0-0235-4cfe-9ba1-2268be20fedc uuid:1eea3723-e463-42e6-b468-f91ad415a4d9 application/pdf PDF Acrobat Web Capture 9.0 endstream endobj 90 0 obj <> endobj 91 0 obj <> endobj 93 0 obj <>/Metadata 89 0 R/Names 94 0 R/Outlines 9 0 R/Pages 83 0 R/SpiderInfo 90 0 R/StructTreeRoot 10 0 R/Type/Catalog/URI<>/ViewerPreferences 118 0 R/Lang(English)/OCProperties 134 0 R>> endobj 94 0 obj <> endobj 95 0 obj <>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<>>>/Rotate 0/StructParents 4/Type/Page/Tabs/S>> endobj 96 0 obj <> endobj 97 0 obj [/ICCBased 106 0 R] endobj 98 0 obj [/Indexed 99 0 R 3 108 0 R] endobj 99 0 obj [/ICCBased 107 0 R] endobj 100 0 obj <> endobj 101 0 obj <>stream /CS0 cs 1 scn 36 766.552 576 -694.552 re f BT /P <>BDC 0 scn /TT0 1 Tf 0.016 Tw 10.5517 0 0 10.5517 85.6552 433.2414 Tm [(James)-55( Duffy)]TJ EMC /P <>BDC 0.008 Tw 8.6897 0 0 8.6897 85.6552 411.5172 Tm [(Patent)-38( Agent)]TJ EMC /Div <>BDC 0 Tw 5.857 0 Td ( )Tj EMC /P <>BDC 0.008 Tw 0.286 0 Td [(and)-46( Senior)-39( Associate)]TJ EMC ET /Img <>BDC q /GS0 gs 93.1034393 0 0 -40.3448334 60.8275909 760.3448029 cm /Im0 Do Q EMC BT /H1 <>BDC /CS2 cs 0.161 0.239 0.239 scn /TT0 1 Tf -0.003 Tw 24.8276 0 0 24.8276 60.8276 649.2413 Tm [(Canadian)-20( Patents:)-6( Federal)-10( Court)-5( confirms)-22( that)]TJ EMC /H1 <>BDC 0 -1.225 TD [(the)-10( PM\(NOC\))-12( Regulations)-20( provide)-21( a)-19( patent)]TJ EMC /H1 <>BDC T* [(enforcement)-17( mechanism)-13( only)-16( in)-22( relation)-21( to)]TJ EMC /H1 <>BDC T* [(products)-15( that)-7( are)-5( in)-22( fact)-13( available)-4( to)-16( Canadians)]TJ EMC /TIME <>BDC /CS0 cs 0 scn -0.028 Tw 9.931 0 0 9.931 60.8276 525.7241 Tm [(October)-5( 19,)-47( 2022)]TJ EMC /H3 <>BDC /CS2 cs 0.427 0.753 0.404 scn 0 Tw 17.3793 0 0 17.3793 60.8276 472.9655 Tm (Author)Tj EMC /P <>BDC /CS0 cs 0 scn 0.016 Tw 10.5517 0 0 10.5517 60.8276 374.8965 Tm [(In)-48( a)-32( recent)-44( Federal)-22( Court)-26( decision,)-54( Justice)-6( Fothergill)-6( dismissed)-25( AbbVie\222s)-54( applications)-14( for)-9( judicial)]TJ EMC /P <>BDC 0 -1.235 TD [(review)-52( of)-48( the)-22( following)-51( decisions)-8( of)-48( the)-22( Minister)-29( of)-48( Health)-51( \(the)-42( \223Minister\224\):)]TJ EMC /P <>BDC 0 -2.176 TD [(that)-38( JAMP)-39( was)-45( not)-22( a)-32( \223second)-31( person\224)-22( for)-9( the)-22( purposes)-5( of)-48( s)-29( 5\(1\))-45( of)-48( the)-22( )]TJ EMC /P <>BDC /TT1 1 Tf [(PM\(NOC\))-24( Regulations)]TJ EMC /P <>BDC /TT0 1 Tf 41.882 0 Td [(;)-16( and)]TJ EMC /P <>BDC -41.882 -2.176 Td [(to)-48( issue)-19( NOCs)-43( to)-48( JAMP)-39( for)-9( its SIMLANDI)-42( Presentations.)]TJ EMC /H2 <>BDC /TT2 1 Tf 0 Tw T* (Background)Tj EMC /P <>BDC /TT0 1 Tf 0.016 Tw T* [(AbbVie's)-26( drug)-58( HUMIRA)-56( first)-36( received)-44( approval)-47( in)-45( Canada)-27( in)-45( 2004)-11( as)-3( a)-32( 50)-6( mg/mL)-3( concentration)-56( of)]TJ EMC /P <>BDC 0 -1.235 TD [(adalimumab.)-41( HUMIRA)-56( is)-43( widely)-46( used)-8( to)-48( treat)-58( numerous)-24( medical)-26( conditions)-27( including)-54( rheumatoid)]TJ EMC /P <>BDC 0 -1.235 TD [(arthritis,)-32( adult)-8( and)-38( pediatric)-45( Crohn\222s)-26( disease,)-41( and)-38( psoriasis.)]TJ EMC /P <>BDC 0 -2.176 TD [(In)-48( 2016,)-27( high)-51(-)-20(concentration)-56( \(100)-58( mg/mL\))-23( HUMIRA)-56( was)-45( approved)-7( in)-45( Canada)-27( in)-46( a)-32( 40)-6( mg/0.4)-2( mL)-23( pre)-26(-)]TJ EMC /P <>BDC 0 -1.235 TD [(filled)-3( syringe)-12( \(DIN)-4( 02458349\),)-59( and)-38( as)-3( a)-32( 40)-6( mg/0.4)-2( mL)-23( pre)-26(-)-20(filled)-3( auto)-54(-)-20(injector)-12( pen)-38( \(DIN)-4( 02458357\).)]TJ EMC /P <>BDC 0 -2.176 TD [(In)-48( fact,)-51( AbbVie)-11( has)-35( marketing)-22( authorization)-40( in)-45( Canada)-27( for)-9( a)-32( variety)-55( of)-48( concentrations,)-42( but)-22( is)-43( actively)]TJ EMC /P <>BDC 0 -1.235 TD [(selling)-48( only:)-6( the)-22( original)-12( \(lower\))-4( 50)-6( mg/mL)-3( concentration)-56( in)-45( 40)-6( mg/0.8)-2( mL)-23( strengths)-5( in)-45( both)-54( auto)-54(-)]TJ EMC /P <>BDC 0 -1.235 TD [(injector)-12( pen)-38( and)-38( pre)-26(-)-20(filled)-3( syringe)-12( presentations,)-13( and)-38( the)-22( newer)-42( \(higher\))-26( 100)-38( mg/mL)-3( concentration)-56( in)]TJ EMC /P <>BDC T* [(a)-32( 20)-6( mg/0.2)-2( mL)-23( pre)-26(-)-20(filled)-3( syringe.)]TJ EMC /P <>BDC 0 -2.176 TD [(In)-48( December)-35( 2020)-11( or)-52( January)-31( 2021,)-27( JAMP)-39( sought)-57( regulatory)-25( approval)-47( in)-45( Canada)-27( for)-9( its SIMLANDI)]TJ EMC /P <>BDC 0 -1.235 TD [(drug,)-15( a)-32( \223biosimilar\224)-53( of)-48( AbbVie\222s)-54( HUMIRA,)-13( in)-46( some)-26( of)-48( the)-22( strengths)-5( not)-22( actively)-19( sold)-48( by)-3( AbbVie)-11( \(i.e.,)-55( a)]TJ EMC /P <>BDC T* [(40)-6( mg/0.4)-2( mL)-23( pre)-25(-)-20(filled)-3( syringe,)-28( a)-32( 40)-6( mg/0.4)-2( mL)-23( auto)-54(-)-20(injector)-12( pen,)-54( and)-38( an)-6( 80)-6( mg/0.8)-2( mL)-23( pre)-26(-)-20(filled)]TJ EMC /P <>BDC 0 -1.235 TD [(syringe\).)-48( In)-48( its NDS,)-23( JAMP)-39( relied)-26( on)-6( three)-15( HUMIRA)-56( drug)-58( products)-47( having)-54( the)-22( same)-26( exact)-22( dosage)]TJ EMC ET endstream endobj 102 0 obj <> endobj 103 0 obj <> endobj 104 0 obj <> endobj 105 0 obj <> endobj 106 0 obj <>stream Hb``$WR~  |@T # 2 S/`M.(*(%8H8c- fԉd9@6_IjH9(3=DR1%?)U!$5X3/9 ($5j%V*'&*r"(,!!0b;CҢ2(ɘ I8/ endstream endobj 107 0 obj <>stream HyTSwoɞc [5laQIBHADED2mtFOE.c}08׎8GNg9w߽'0 ֠Jb  2y.-;!KZ ^i"L0- @8(r;q7Ly&Qq4j|9 V)gB0iW8#8wթ8_٥ʨQQj@&A)/g>'Kt;\ ӥ$պFZUn(4T%)뫔0C&Zi8bxEB;Pӓ̹A om?W= x-[0}y)7ta>jT7@tܛ`q2ʀ&6ZLĄ?_yxg)˔zçLU*uSkSeO4?׸c. R ߁-25 S>ӣVd`rn~Y&+`;A4 A9=-tl`;~p Gp| [`L`< "A YA+Cb(R,*T2B- ꇆnQt}MA0alSx k&^>0|>_',G!"F$H:R!zFQd?r 9\A&G rQ hE]a4zBgE#H *B=0HIpp0MxJ$D1D, VĭKĻYdE"EI2EBGt4MzNr!YK ?%_&#(0J:EAiQ(()ӔWT6U@P+!~mD eԴ!hӦh/']B/ҏӿ?a0nhF!X8܌kc&5S6lIa2cKMA!E#ƒdV(kel }}Cq9 N')].uJr  wG xR^[oƜchg`>b$*~ :Eb~,m,-ݖ,Y¬*6X[ݱF=3뭷Y~dó ti zf6~`{v.Ng#{}}jc1X6fm;'_9 r:8q:˜O:ϸ8uJqnv=MmR 4 n3ܣkGݯz=[==<=GTB(/S,]6*-W:#7*e^YDY}UjAyT`#D="b{ų+ʯ:!kJ4Gmt}uC%K7YVfFY .=b?SƕƩȺy چ k5%4m7lqlioZlG+Zz͹mzy]?uuw|"űNwW&e֥ﺱ*|j5kyݭǯg^ykEklD_p߶7Dmo꿻1ml{Mś nLl<9O[$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)Km endstream endobj 108 0 obj <>stream tdBLR endstream endobj 109 0 obj <> endobj 110 0 obj <>/Filter/FlateDecode/Height 175/Length 6099/Name/X/Subtype/Image/Type/XObject/Width 400>>stream H{tMWoOixgo`1BhhFPh1af0!ڹMA"Z 3(Z) D3=>scܵfHۿ_CPՒv#8JC>nwl:R<[] m(!Uv!P{%d^Tp B7(@eǝH( k^@>$fi!Iu6UL" Aj kDg-juV cwY/wV2 =Oqӆ=BWD/ c;Cy|h2pheRk]<^gW_a:֎uKn$g԰uT0EŶuz_k#ipĶ|L_Տ,Ͳ zOV~YfW{ yǭ8 FX.UtGfXpս.׺f84"ۿ23T}*T6.h˛{yyYb*y "qX׍jjs'bG)?c$icG#"kQRSUX}mMlSS~HY#\M{[1DwLW+XDTI^]km7tprvb3 QǐH b.(5`;jF$(3u 204| &upeQlZrZI*R\K2{/b( HQ^+;r^ݥ3lKʒyLYUaS N"qb]MC^ _w~n-pV: -r<0=jނzѢF_  0WXK-C9U/¾[pD}] 9 ʡp}L1ƞW#JSU }/[LJU8a[VT cx=$ G!锤:U]oJ㈮K}E)sMrt}ædVgk=^Bk5m5_E\\AI%; {;V&\Cn՛jmj&jx} U6s42%ʿUJrN\v2-Mo_E&[sǫ*<}"QxNIC|%ol3#(Xjje&4j״u=5 " I{nE5j>oKR7kcVn9e0%D. -R4Lm*v_K"ֿXyG،y3}n_x.Aф( ~PfWPɮxw^ Q.Co]ɭ}~ "n6 Nr%d}I|1*NI$W-y%X 8-5ii|YFRfzHI* Z%, a6F~RqCCS͇=Ovp)) u8LgD$a\P`h#*FM&V+rZ*f=BJR'x7T`Gok?`5y&_&T )KnbyK@2U+_BxɌ=%üo%x%ʇeFImNZZGŐT[ =0@{)I d*oሑ)I)g\G'A " $پCABʈb7O>t x 1Ϛ9| .N%:#8uqd51 @?c_ i d#%̃$n/ ِ (t|@! n/*Q>JvB& ( \ @ @ @ @  i7ryf'\pί%0NDx3 |Zl?̨KhYt8mDi~lxRC`@1"X-Ƿ{H7*Ћf}6|>ɥ YAݜ>\ @a@a%3I8oh']_Ώɗ9k3HP?=e5v qkMy ̇#}ȼcn4hiG! +C|8eG=ny䨻]sl`s\&|4ʌv>z }w}+|y#te˴aqy1Ԩ;"]L7vݩ\)O颛3A>jZH-/w zix>1cn Ǝ;Yq ak9C:ϥѭϵnG {j1&~;YKa9Cj}:Ԍsˎ5Z5&n;mq{ps5ǍVYe ; Uh=!q2|q˸9ClqBҵXNO#P뭴5sIkqǑ??޵I|B۴/68(k0Ks.-ǯ;X}taZRȤXm3Y/$eqV{kM}GKhc܃0By p# D,8X "j+b2HF 4By- ȣw IH{/ܵگou~7U`1FA]Kk^?cw|xF%Pwx !QZZץW]Qü;;!8,,nNۄ_5{|wi1;ɴ3~E x4+B5!sy!M{zՌY^jb·+cuj*b#J_[ũFGi =Ҵ<8C % p#v3:a4@;5<>!{zJ"v+ySuV!m,f$|*PGZ1j}"GRqX ]<ԃR ەA𾒝8_/XMU8@z%T 7AUD"~nS(* 5!QoQ?!īڑ !.w,oA'рx֤UBa6=xG󋨁MPѢj*0fOv!Ļ8сy,6 {xjAx,%,z7_YhQ} Ļ`QH`F('cL9¥? zEM8ax&PI j"&ǢzkP S¥կ%MI]#oQQ3 Aau Lx%j 9Qmcl(J c 0u12C냥5 F'G. ˟0f܁wl1Fxx^h@7^~82<ʇ AZwj(~=Bnbz2`w$7 'CɜV 2;736 @ol|AgYypktul;12̔G̿p^Xoa}ҳYLgz^<}TAT!z>I8#>%CHUxp^j‶,ił&_<];YU}3gT@@se$GUGO:8D!j&&D !VWGJzB,y?5VQ*ȊGop$sAE%%> V/"b#|iyXmȑ7kO/MkaI܅Ip}8,ڂ=;ts^a@bǃ-'NSF`,.c%1ot<:SWx/?j}d%,y dh:DV}<ªPa/.|Xt̉uW3w㹎&/"p푟SC팚nh^>32k+&؝>L:W>v#:Ƽdӑ“y+>pkP\Qo{*RTٽk߷ƭ.BUQXWkrI,J'wxrK>o-<%|ޒ[yxK>>Ϩ ʽ5?-<%|ޒ[yxK>o-<\A ouM|yD`^D endstream endobj 111 0 obj <>stream HZu{7U׌ek^n_]W5qW k C Q/2{'Imek6  ã&Q '#0&Wt]x̡^aJfO,,R 0u5,|GC":`!YOu&A":&H+ün&ȃ邆 w̃P,\  (\A<02^<xd46cUVVJ\í'ܠh0߭9h3[b׋VG4;^G-RAG;I;<ƞwSL9<> endobj 113 0 obj (q* X85I) endobj 114 0 obj [/ICCBased 115 0 R] endobj 115 0 obj <>stream HyTSwoɞc [5laQIBHADED2mtFOE.c}08׎8GNg9w߽'0 ֠Jb  2y.-;!KZ ^i"L0- @8(r;q7Ly&Qq4j|9 V)gB0iW8#8wթ8_٥ʨQQj@&A)/g>'Kt;\ ӥ$պFZUn(4T%)뫔0C&Zi8bxEB;Pӓ̹A om?W= x-[0}y)7ta>jT7@tܛ`q2ʀ&6ZLĄ?_yxg)˔zçLU*uSkSeO4?׸c. R ߁-25 S>ӣVd`rn~Y&+`;A4 A9=-tl`;~p Gp| [`L`< "A YA+Cb(R,*T2B- ꇆnQt}MA0alSx k&^>0|>_',G!"F$H:R!zFQd?r 9\A&G rQ hE]a4zBgE#H *B=0HIpp0MxJ$D1D, VĭKĻYdE"EI2EBGt4MzNr!YK ?%_&#(0J:EAiQ(()ӔWT6U@P+!~mD eԴ!hӦh/']B/ҏӿ?a0nhF!X8܌kc&5S6lIa2cKMA!E#ƒdV(kel }}Cq9 N')].uJr  wG xR^[oƜchg`>b$*~ :Eb~,m,-ݖ,Y¬*6X[ݱF=3뭷Y~dó ti zf6~`{v.Ng#{}}jc1X6fm;'_9 r:8q:˜O:ϸ8uJqnv=MmR 4 n3ܣkGݯz=[==<=GTB(/S,]6*-W:#7*e^YDY}UjAyT`#D="b{ų+ʯ:!kJ4Gmt}uC%K7YVfFY .=b?SƕƩȺy چ k5%4m7lqlioZlG+Zz͹mzy]?uuw|"űNwW&e֥ﺱ*|j5kyݭǯg^ykEklD_p߶7Dmo꿻1ml{Mś nLl<9O[$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD-u`ֲK³8%yhYѹJº;.! zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs 2F[p(@Xr4Pm8Ww)Km endstream endobj 118 0 obj <> endobj 121 0 obj <> endobj 122 0 obj <> endobj 123 0 obj <> endobj 124 0 obj <> endobj 125 0 obj <> endobj 126 0 obj <> endobj 127 0 obj <>stream xڵKKC1>hZ_]f$Vнp7 (a(Tr gfNBցk}> a2*k3:kXoJ(di\$ TJMx'`Kxzpa} ~ѣ endstream endobj 128 0 obj <> endobj 129 0 obj <> endobj 130 0 obj <> endobj 131 0 obj <> endobj 132 0 obj <> endobj 133 0 obj <> endobj 134 0 obj <> endobj 135 0 obj <> endobj 136 0 obj <> endobj 137 0 obj <> endobj 138 0 obj <> endobj 139 0 obj <> endobj 140 0 obj <> endobj 141 0 obj <> endobj 142 0 obj <>stream q endstream endobj 143 0 obj <>stream x w,*LKL.Q,HUHLK,ϳSprq-53P0bdvr.{Bz1[K>o 3/T4 endstream endobj 146 0 obj <> endobj 147 0 obj <> endobj 148 0 obj <> endobj 149 0 obj <> endobj 150 0 obj <> endobj 151 0 obj <>stream xڵKKC1>hZ_]f$Vнp7 (a(Tr gfNBցk}> a2*k3:kXoJ(di\$ TJMx'`Kxzpa} ~ѣ endstream endobj 152 0 obj <> endobj 153 0 obj <> endobj 154 0 obj <> endobj 155 0 obj <> endobj 156 0 obj <> endobj 157 0 obj <> endobj 158 0 obj <> endobj 159 0 obj <> endobj 160 0 obj <> endobj 161 0 obj <> endobj 162 0 obj <> endobj 163 0 obj <> endobj 164 0 obj <> endobj 165 0 obj <> endobj 166 0 obj <>stream q endstream endobj 167 0 obj <>stream x w,*LKL.Q,HUHLK,ϳSprq-53P0bdvr.{Bz1[K>o 3/T4 endstream endobj 170 0 obj <> endobj 171 0 obj <> endobj 172 0 obj <> endobj 173 0 obj <> endobj 174 0 obj <> endobj 175 0 obj <>stream xڵKKC1>hZ_]f$Vнp7 (a(Tr gfNBցk}> a2*k3:kXoJ(di\$ TJMx'`Kxzpa} ~ѣ endstream endobj 176 0 obj <> endobj 177 0 obj <> endobj 178 0 obj <> endobj 179 0 obj <> endobj 180 0 obj <> endobj 181 0 obj <> endobj 182 0 obj <> endobj 183 0 obj <> endobj 184 0 obj <> endobj 185 0 obj <> endobj 186 0 obj <> endobj 187 0 obj <> endobj 188 0 obj <> endobj 189 0 obj <> endobj 190 0 obj <>stream q endstream endobj 191 0 obj <>stream x w,*LKL.Q,HUHLK,ϳSprq-53P0bdvr.{Bz1[K>o 3/T4 endstream endobj 192 0 obj <>stream xz tUwoUuuZ$Y:4!,HM  IH, I]PGq qN҉((3ˌ:PgTqtVw{yw;Uno4V gpm?Bcjl^ߣ\Q9 @;Waո4?4aŪM˿X'B[kSgx /hC 籝ڶg{:}ͪ& ޺ic' @ʚխo`v>y粢rNb5 yLrXNZ5oB߇œ| Os ^Y@Su">{N\o ,FG=ngTx?YB_:  #id Fv\"-7G?9KǷ{;;?ч👦.H8 T mݏ!#3|$&K&"Ar#oD9~w A(3z#l _AjiH,V\f O!; oH9 _؉$d2ԒEd!ȍvG!?n hddM皠=kuQ-h=ڧaOzCC6y>$9;}̡sJ>n%4@jh, rQw(I;J7+'ObhzT kQ ( a& ,!w>N;978LWpmˍ'7,< 4^ep; ϓ;d io5\P'#y~>.Z<ގMB)B5"ߠ܄T* 0J:UT41dIK~7N\2ibqQ92}cxR=)nŕtmVl6 z5^/JOU6xgڴ,4!@c@AP8QES.#G01@IVRQ+\"|S'm7t+ۻM 쫭zҴ*\z'37¶ώ9TAV{u#^H|onrC|;&x*;w`_'+_Do2G+㥕֋}jMEgI؎<ӑ J;AXZEO=QT+Odp6> [krHSIVeq/rH=!+s}x:e $̩an7A?,F`km]gYz\A=Q1YUM IwkzvQRmZ}ZV^%h&pj/r⒋ȬQgiQ9%(jUQrH^s(iXtۓ.k_=C/潴z^e}Uwz{nZXVߟ}uC ZJYCa &T' W{yTvF9H#09W]ȏnGsGyi#({d3 A@qhEsyzQco$з7vK:+}B1!; o[>p'%;姀 㤍C`sã'(HcJg  1d޾(faBWGLKS.y}KÜEK7+;NQ;kNPsoW9hX'\gɅyPޓsMm9oO~qg/ym呾]*c\,عvC _?B/wݗݸ}{k"Ԏ?ҵʼ(fY3Uטi8//1 2j->Q޹lrJ~rk^C++6F&V bALjȲ)ɥi:8\&%LKi| a kԁ#Ɍ_fJNdtRtMq|rWO濣Am6ˬ|RDBJ1Y>b)&]+x2ZAah\FIX$5Jaܻ_Yх'7[⺪?yCcֲPܝMzcY/o7uYzl۞w)9zM'H1Vr2EFV+M&H ؈3rhh҉2gԚM&Nhub3d?N"!\N3gT6*-[zq>!Jk"%*),x‚B. yB_40%3b|ew7?)ǹcG>ۻBMi TPp޿EnhwKkܯ}tiJDr<"i5(A I Y*h#Foרf#t,1Vym 7vK!>LRc`C-Vg}?1V"!MyN֑ һFSNmLݚʧID))iEM>6k]oya_-P r%_SbP:QiD9wnG隒ef|;>-tn r̺y\CO GB;aeM1op7mSGk\H 2[*%pZ!D4y&HqkFV+7n _֡WIp#H~5c,S[Bla,SCewaF<` ,Rd屩c<[wy(tlCouB?Q A&Jђωbq,- EnN* cZ 3X EU@U[^"eT32)T2Duw:|M`h|Gϔ6_u͹ ,W_Q4=WY; }zo[p[ͽ͕ESYhWK1)..X06iaU_4nxu{&AaQUQ7OdJU=zE@Ng>F,AЏS>:H2*8JVF/IQZ(ǻ):ɝh&H^^$ǁN! V/<:f> };5\0`|JH̫i SM=CE~v On#nM˅vVYc(4X[VDYMm dHe1YTQF!qftZ\xF[ج^DmdlSD;jIсU=ƵF!J%B{Z9E%Q_F\6^YUã^ԶkOmPP}*өShɢY䈬 "j$ꥢ1i((T w F-$-&=|" ; ̾a '^SfA# 7Kb*J=1Lzj5:S X$lGfsIoG,Yϥ.!tƀ'Uei9l265Ur8FyI\&GC5^û#<}mQT.e3'QG5˶?&OQlIFEcjl \#ɣ+_yœK:?h/۶'xq&^6" O>uKϤzC_˝Gq~f0XJQCܽgq_sF d:ť^FGohmmV+o6$$ب%$r;ٍqQR?%&#[Sitjj4DA_EUh@T/kQZ.0a&LO@BD}:c޽m3}^R~r ݂/v]t='W>$xJt4\:X0`5> `e;nW1H[0qHбqGw7Pk@@x|} 2JīԻhVp@h] h]e( 90CbYz|trluaMoW1aTXs@jŲcޢb񝆭em ξ]g&ξ ^(8oXo:duρ_ܺuڪ^ڢ@Nv@u֞UvBBҺkұ?eթDz`>`/Ei햋5IgѦy =0(r@d' Z029sx|68`?T-gne̚\)uH)M9y ʍ`H;c|Q957cx\0Ά=2k>AAGp#:[3["5U|yRl5/Ujޡ*>9~s2 Idg ]D/wS]+\X0mɘΨpwEGA ҁ[ӽ.8ZQ }ju!+H~pd+H럮g]ߺf^x5X X2)ٵ57wƵѵʵFQV]8hQ"WdRUp4G]Y$ՕeCƻ\\rFΊ1XJkQ2J}}žľb$@ }bOKD֪&Aj-ZЪ?H1oήYYΫuFaJUYUye:p)yDW( xHZ ˜"_uP u^$0.H!ոoK`e!v}:R\U?%Ĝ"ionPtM9}ǚΤ]O&rY%T_3OYR7D++32ʹ eVWըxAV (exP}GIϣ!EbxX2d `9>d/%xÞʊ~gtag82WDEqRQPT\*P'(ʸ(ԕ8+cTFql%i-*̩BY}H+wNQ7屄a-},AiS1411Inu <*hWԬ uد٣]&Ɂh` q>{zg]@Ƽ@i~Q +3 +80 ]D("RL2E q n .t){՜mVݞ;* endstream endobj 193 0 obj <> endobj 194 0 obj <> endobj 195 0 obj <> endobj 196 0 obj <>stream xړy endstream endobj 197 0 obj <>stream x]n0< HRJ9tj!m r!o_4Eai\?~Z|=J]| Vh 6&[~KeL>ݯ\~ʏ;=ѫE'8 ?Gy8%r-?_*[/Be|>}Z)hNKo%,ŞxQ_ 1-2QSbKGT]5h Z6-h;n@7tԀ@wZAc{AԂZP:PnAT;qiZ,(V`PjX (:3ZҒc nAd ; &[&aդPLK Xeh~(m<]c- [qÛv8^˼| endstream endobj xref 0 198 0000000000 65535 f 0000000016 00000 n 0000000366 00000 n 0000009999 00000 n 0000010233 00000 n 0000010598 00000 n 0000010621 00000 n 0000017093 00000 n 0000018277 00000 n 0000018496 00000 n 0000018538 00000 n 0000018658 00000 n 0000018704 00000 n 0000018754 00000 n 0000018819 00000 n 0000018926 00000 n 0000019266 00000 n 0000019820 00000 n 0000020282 00000 n 0000020358 00000 n 0000020423 00000 n 0000020661 00000 n 0000020710 00000 n 0000020765 00000 n 0000020846 00000 n 0000020909 00000 n 0000020959 00000 n 0000021022 00000 n 0000021081 00000 n 0000021139 00000 n 0000021191 00000 n 0000021245 00000 n 0000021295 00000 n 0000021349 00000 n 0000021396 00000 n 0000021468 00000 n 0000021516 00000 n 0000021564 00000 n 0000021612 00000 n 0000021665 00000 n 0000021721 00000 n 0000021770 00000 n 0000021820 00000 n 0000021876 00000 n 0000021929 00000 n 0000021988 00000 n 0000022163 00000 n 0000022229 00000 n 0000022302 00000 n 0000022366 00000 n 0000022430 00000 n 0000022485 00000 n 0000022534 00000 n 0000022601 00000 n 0000022668 00000 n 0000022720 00000 n 0000022772 00000 n 0000022827 00000 n 0000022902 00000 n 0000022951 00000 n 0000023036 00000 n 0000023100 00000 n 0000023148 00000 n 0000023196 00000 n 0000023254 00000 n 0000023322 00000 n 0000023390 00000 n 0000023458 00000 n 0000023511 00000 n 0000023567 00000 n 0000023619 00000 n 0000023666 00000 n 0000023718 00000 n 0000023766 00000 n 0000023817 00000 n 0000023864 00000 n 0000023926 00000 n 0000023974 00000 n 0000024025 00000 n 0000024072 00000 n 0000024128 00000 n 0000024175 00000 n 0000024230 00000 n 0000024272 00000 n 0000024337 00000 n 0000024380 00000 n 0000024422 00000 n 0000024538 00000 n 0000024656 00000 n 0000024709 00000 n 0000028219 00000 n 0000028247 00000 n 0000000000 65535 f 0000028384 00000 n 0000028638 00000 n 0000028695 00000 n 0000029114 00000 n 0000030291 00000 n 0000030327 00000 n 0000030371 00000 n 0000030407 00000 n 0000030629 00000 n 0000035558 00000 n 0000036743 00000 n 0000036972 00000 n 0000038154 00000 n 0000038382 00000 n 0000038671 00000 n 0000041319 00000 n 0000041380 00000 n 0000041494 00000 n 0000047815 00000 n 0000050015 00000 n 0000050063 00000 n 0000050099 00000 n 0000050136 00000 n 0000000000 65535 f 0000000000 65535 f 0000052804 00000 n 0000000000 65535 f 0000000000 65535 f 0000052847 00000 n 0000052901 00000 n 0000052947 00000 n 0000053050 00000 n 0000053115 00000 n 0000053283 00000 n 0000053423 00000 n 0000053965 00000 n 0000054049 00000 n 0000054086 00000 n 0000054119 00000 n 0000054154 00000 n 0000054191 00000 n 0000054249 00000 n 0000054311 00000 n 0000054458 00000 n 0000054527 00000 n 0000054597 00000 n 0000054651 00000 n 0000054699 00000 n 0000054774 00000 n 0000054821 00000 n 0000054871 00000 n 0000000000 65535 f 0000000000 65535 f 0000055023 00000 n 0000055077 00000 n 0000055123 00000 n 0000055226 00000 n 0000055291 00000 n 0000055459 00000 n 0000056001 00000 n 0000056085 00000 n 0000056122 00000 n 0000056155 00000 n 0000056190 00000 n 0000056227 00000 n 0000056285 00000 n 0000056354 00000 n 0000056424 00000 n 0000056478 00000 n 0000056526 00000 n 0000056601 00000 n 0000056648 00000 n 0000056682 00000 n 0000056716 00000 n 0000056766 00000 n 0000000000 65535 f 0000000000 65535 f 0000056918 00000 n 0000056972 00000 n 0000057018 00000 n 0000057121 00000 n 0000057186 00000 n 0000057354 00000 n 0000057896 00000 n 0000057980 00000 n 0000058017 00000 n 0000058050 00000 n 0000058085 00000 n 0000058122 00000 n 0000058180 00000 n 0000058249 00000 n 0000058319 00000 n 0000058373 00000 n 0000058421 00000 n 0000058496 00000 n 0000058543 00000 n 0000058577 00000 n 0000058611 00000 n 0000058661 00000 n 0000058813 00000 n 0000068620 00000 n 0000068690 00000 n 0000068939 00000 n 0000069305 00000 n 0000069387 00000 n trailer <]/Size 198>> startxref 69862 %%EOF